Cancer exploiting complement: a clue or an exception?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.British journal of cancer · 2010
   Trial
2. Multi-omic diagnostics of prostate cancer in the presence of benign prostatic hyperplasia.Heliyon · 2023
   Article
3. Chemotherapy-induced complement signaling modulates immunosuppression and metastatic relapse in breast cancer.Nature communications · 2022
   Article
4. High complement protein C1q levels in pulmonary fibrosis and non-small cell lung cancer associated with poor prognosis.BMC cancer · 2022
   Article
5. Anti gC1qR/p32/HABP1 Antibody Therapy Decreases Tumor Growth in an Orthotopic Murine Xenotransplant Model of Triple Negative Breast Cancer.Antibodies (Basel, Switzerland) · 2020
   Article
6. PTX3 modulates the immunoflogosis in tumor microenvironment and is a prognostic factor for patients with clear cell renal cell carcinoma.Aging · 2020
   Article
7. Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics.Science immunology · 2020
   Article
8. Complementing Cancer Metastasis.Frontiers in immunology · 2018
   Review
9. Extracellular vesicles from KSHV-infected endothelial cells activate the complement system.Oncotarget · 2017
   Article
10. C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation.Nature communications · 2016
    Article
11. Modulatory Role of Surface Coating of Superparamagnetic Iron Oxide Nanoworms in Complement Opsonization and Leukocyte Uptake.ACS nano · 2015
    Article
12. Complement anaphylatoxins as immune regulators in cancer.Cancer medicine · 2014
    Review
13. Unwelcome complement.Cancer research · 2009
    Review
14. Is complement good or bad for cancer patients? A new perspective on an old dilemma.Trends in immunology · 2009
    Review
15. Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy.Oncoimmunology
    Article

Corrections and comments

• Comment on
  Modulation of the antitumor immune response by complement.2008

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as